Epstein-Barr Virus Vaccine, Phase I

[NHE]

Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.

https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine

It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.

https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1